- Home
- IMCR vs ROOT Comparison
IMCR vs ROOT Comparison
Compare IMCR & ROOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- ROOT
- Stock Information
- Founded
- IMCR 2008
- ROOT 2015
- Country
- IMCR United Kingdom
- ROOT United States
- Employees
- IMCR N/A
- ROOT N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- ROOT Property-Casualty Insurers
- Sector
- IMCR Health Care
- ROOT Finance
- Exchange
- IMCR Nasdaq
- ROOT Nasdaq
- Market Cap
- IMCR 1.4B
- ROOT 1.7B
- IPO Year
- IMCR 2021
- ROOT 2020
- Fundamental
- Price
- IMCR $28.41
- ROOT $129.74
- Analyst Decision
- IMCR Buy
- ROOT Buy
- Analyst Count
- IMCR 12
- ROOT 7
- Target Price
- IMCR $60.90
- ROOT $101.33
- AVG Volume (30 Days)
- IMCR 403.7K
- ROOT 727.2K
- Earning Date
- IMCR 05-07-2025
- ROOT 05-07-2025
- Dividend Yield
- IMCR N/A
- ROOT N/A
- EPS Growth
- IMCR N/A
- ROOT N/A
- EPS
- IMCR N/A
- ROOT 1.83
- Revenue
- IMCR $310,202,000.00
- ROOT $1,176,500,000.00
- Revenue This Year
- IMCR $20.52
- ROOT $12.28
- Revenue Next Year
- IMCR $8.57
- ROOT $12.34
- P/E Ratio
- IMCR N/A
- ROOT $70.90
- Revenue Growth
- IMCR 24.36
- ROOT 158.57
- 52 Week Low
- IMCR $23.15
- ROOT $34.04
- 52 Week High
- IMCR $62.74
- ROOT $181.14
- Technical
- Relative Strength Index (RSI)
- IMCR 51.56
- ROOT 50.54
- Support Level
- IMCR $26.37
- ROOT $113.59
- Resistance Level
- IMCR $27.67
- ROOT $134.53
- Average True Range (ATR)
- IMCR 1.76
- ROOT 11.77
- MACD
- IMCR 0.10
- ROOT -0.40
- Stochastic Oscillator
- IMCR 77.93
- ROOT 76.50
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About ROOT Root Inc.
Root Inc develops and launches a direct-to-consumer personal automobile insurance and mobile technology company. The company is a direct-to-consumer personal auto insurance, renters insurance and mobile technology company. It generates revenue from the sales of auto insurance policies within the United States.